|
1
|
Carcas LP: Gastric cancer review. J
Carcinogenesis. 13:142013. View Article : Google Scholar
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guggenheim DE and Shah MA: Gastric cancer
epidemiology and risk factors. J Surg Oncol. 107:230–236. 2013.
View Article : Google Scholar
|
|
4
|
Wadhwa R, Taketa T, Sudo K, Blum MA and
Ajani JA: Modern oncological approaches to gastric adenocarcinoma.
Gastroenterol Clin North Am. 42:359–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee JH, Kim Y, Choi JW and Kim YS: Genetic
variants and risk of gastric cancer: A pathway analysis of a
genome-wide association study. Springerplus. 4:2152015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ang TL and Fock KM: Clinical epidemiology
of gastric cancer. Singapore Med J. 55:621–628. 2014. View Article : Google Scholar
|
|
7
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al: Capecitabine and cisplatin with or without cetuximab for
patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coburn NG: Lymph nodes and gastric cancer.
J Surg Oncol. 99:199–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wildeboer D, Naus S, Amy Sang QX, Bartsch
JW and Pagenstecher A: Metalloproteinase disintegrins ADAM8 and
ADAM19 are highly regulated in human primary brain tumors and their
expression levels and activities are associated with invasiveness.
J Neuropathol Exp Neurol. 65:516–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reiss K and Saftig P: The ‘a disintegrin
and metalloprotease’ (ADAM) family of sheddases: Physiological and
cellular functions. Semin Cell Dev Biol. 20:126–137. 2009.
View Article : Google Scholar
|
|
11
|
Kim KE, Song H, Hahm C, Yoon SY, Park S,
Lee HR, Hur DY, Kim T, Kim CH, Bang SI, et al: Expression of ADAM33
is a novel regulatory mechanism in IL-18-secreted process in
gastric cancer. J Immunol. 182:3548–3555. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carl-Mcgrath S, Lendeckel U, Ebert M,
Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9,
ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol.
26:17–24. 2005.
|
|
13
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murphy G: The ADAMs: Signalling scissors
in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gall SML, Bobé P, Reiss K, Horiuchi K, Niu
XD, Lundell D, Gibb DR, Conrad D, Saftig P and Blopel CP: ADAMs 10
and 17 represent differentially regulated components of a general
shedding machinery for membrane proteins such as transforming
growth factor alpha, L-selectin, and tumor necrosis factor alpha.
Mol Biol Cell. 20:1785–1794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lorenzen I, Trad A and Grötzinger J:
Multimerisation of A disintegrin and metalloprotease protein-17
(ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res
Commun. 415:330–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ni SS, Zhang J, Zhao WL, Dong XC and Wang
JL: ADAM17 is overexpressed in non-small cell lung cancer and its
expression correlates with poor patient survival. Tumour Biol.
34:1813–1818. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franovic A, Robert I, Smith K, Kurban G,
Pause A, Gunaratnam L and Lee S: Multiple acquired renal carcinoma
tumor capabilities abolished upon silencing of ADAM17. Cancer Res.
66:8083–8090. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen H, Li L, Zhou S, Yu D, Yang S, Chen
X, Wang D, Zhong S, Zhao J and Tang J: The role of ADAM17 in
tumorigenesis and progression of breast cancer. Tumour Biol. 2016.
View Article : Google Scholar
|
|
20
|
Shou ZX, Jin X and Zhao ZS: Upregulated
expression of ADAM17 is a prognostic marker for patients with
gastric cancer. Ann Surg. 256:1014–1022. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang TC, Zhu WG, Huang MD, Fan RH and
Chen XF: Prognostic value of ADAM17 in human gastric cancer. Med
Oncol. 29:2684–2690. 2012. View Article : Google Scholar
|
|
22
|
Chen JT, Yao KH, Hua L, Zhang LP, Wang CY
and Zhang JJ: MiR-338-3p inhibits the proliferation and migration
of gastric cancer cells by targeting ADAM17. Int J Clin Exp Pathol.
8:10922–10928. 2015.PubMed/NCBI
|
|
23
|
Fang W, Qian J, Wu Q, Chen Y and Yu G:
ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic
sign in gastric carcinoma. J Surg Res. 220:223–233. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu M, Zhou H, Zhang C, He J, Wei H, Zhou
M, Lu Y, Sun Y, Ding JW, Zeng J, et al: ADAM17 promotes
epithelial-mesenchymal transition via TGF-β/Smad pathway in gastric
carcinoma cells. Int J Oncol. 49:2520–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Cory G: Scratch-wound assay. Methods Mol
Biol. 769:25–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marrelli D, De Stefano A, de Manzoni G,
Morgagni P, Di Leo A and Roviello F: Prediction of recurrence after
radical surgery for gastric cancer: A scoring system obtained from
a prospective multicenter study. Ann Surg. 241:247–255. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Torres-Collado AX and Iruela-Arispe ML:
Contribution of ADAMs and ADAMTSs to tumor expansion and
metastasis. Cancer Genome and Tumor Microenvironment.
Thomas-Tikhonenko Andrei: Springer; New York, NY: pp. 293–314.
2010, View Article : Google Scholar
|
|
30
|
Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL,
Chang YC, Chiou GY, Chou MY and Chiou SH: miR145 targets the
SOX9/ADAM17 axis to inhibit tumor-initiating cells and
IL-6-mediated paracrine effects in head and neck cancer. Cancer
Res. 73:3425–3440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mężyk-Kopeć R, Wyroba B, Stalińska K,
Próchnicki T, Wiatrowska K, Kilarski WW, Swartz MA and Bereta J:
ADAM17 promotes motility, invasion, and sprouting of lymphatic
endo-thelial cells. PLoS One. 10:e01326612015. View Article : Google Scholar
|
|
32
|
Saaristo A, Karpanen T and Alitalo K:
Mechanisms of angio-genesis and their use in the inhibition of
tumor growth and metastasis. Oncogene. 19:6122–6129. 2000.
View Article : Google Scholar
|
|
33
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in tumorigenesis and angiogenesis. Biochim Biophys Acta.
1784:150–158. 2008. View Article : Google Scholar
|
|
34
|
Gooz P, Gooz M, Baldys A and Hoffman S:
ADAM_17: A central regulator of angiogenesis. Matrix Biology.
25:S55–S56. 2006. View Article : Google Scholar
|
|
35
|
Klein T and Bischoff R: Active
metalloproteases of the A Disintegrin and Metalloprotease (ADAM)
family: Biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar
|
|
36
|
Zheng X, Jiang F, Katakowski M, Lu Y and
Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol
Carcinog. 51:150–164. 2012. View Article : Google Scholar
|
|
37
|
Lv X, Li Y, Qian M, Ma C, Jing H, Wen Z
and Qian D: ADAM17 silencing suppresses the migration and invasion
of non-small cell lung cancer. Mol Med Rep. 9:1935–1940. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mcgowan PM, Ryan BM, Hill AD, Mcdermott E,
O’Higgins N and Duffy MJ: ADAM-17 expression in breast cancer
correlates with variables of tumor progression. Clin Cancer Res.
13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiang J, Fu X, Ran W and Wang Z: Grhl2
reduces invasion and migration through inhibition of TGFβ-induced
EMT in gastric cancer. Oncogenesis. 6:e2842017. View Article : Google Scholar
|
|
41
|
Wu K, Liao M, Liu B and Deng Z: ADAM-17
over-expression in gallbladder carcinoma correlates with poor
prognosis of patients. Med Oncol. 28:4752011. View Article : Google Scholar
|
|
42
|
McGowan PM, Mckiernan E, Bolster F, Ryan
BM, Hill AD, Mcdermott EW, Evoy D, O’Higgins N, Crown J and Duffy
MJ: ADAM-17 predicts adverse outcome in patients with breast
cancer. Ann Oncol. 19:1075–1081. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gooz M: ADAM-17: The enzyme that does it
all. Crit Rev Biochem Mol Biol. 45:146–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rose-John S: ADAM17, shedding, TACE as
therapeutic targets. Pharmacol Res. 71:19–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Aydin D, Bilici A, Yavuzer D, Kefeli U,
Tan A, Ercelep O, Mert A, Yuksel S, Ozcelik M, Isik D, et al:
Prognostic significance of ADAM17 expression in patients with
gastric cancer who underwent curative gastrectomy. Clin Transl
Oncol. 17:604–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kyula JN, Schaeybroeck SV, Doherty J,
Fenning CS, Longley DB and Johnston PG: Chemotherapy-induced
activation of ADAM-17: A novel mechanism of drug resistance in
colorectal cancer. Clin Cancer Res. 16:3378–3389. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hu YY, Zheng MH, Zhang R, Liang YM and Han
H: Notch signaling pathway and cancer metastasis. Adv Exp Med Biol.
727:186–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Du X, Cheng Z, Wang YH, Guo ZH, Zhang SQ,
Hu JK and Zhou ZG: Role of Notch signaling pathway in gastric
cancer: A meta-analysis of the literature. World J Gastroenterol.
20:9191–9199. 2014.PubMed/NCBI
|
|
49
|
Brzozowa M, Mielańczyk Ł, Michalski M,
Malinowski Ł, Kowalczyk-Ziomek G, Helewski K, Harabin-Słowińska M
and Wojnicz R: Role of Notch signaling pathway in gastric cancer
pathogenesis. Contemp Oncol (Pozn). 17:1–5. 2013.
|
|
50
|
Xi Y and Chen Y: Wnt signaling pathway:
Implications for therapy in lung cancer and bone metastasis. Cancer
Lett. 353:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan
J, Wu J and Li M: MicroRNA-374a activates Wnt/β-catenin signaling
to promote breast cancer metastasis. J Clin Invest. 123:566–579.
2013.PubMed/NCBI
|
|
52
|
Jang GB, Kim JY, Cho SD, Park KS, Jung JY,
Lee HY, Hong IS and Nam JS: Blockade of Wnt/β-catenin signaling
suppresses breast cancer metastasis by inhibiting CSC-like
phenotype. Sci Rep. 5:124652015. View Article : Google Scholar
|
|
53
|
Yanaka Y, Muramatsu T, Uetake H, Kozaki KI
and Inazawa J: miR-544a induces epithelial-mesenchymal transition
through the activation of WNT signaling pathway in gastric cancer.
Carcinogenesis. 36:1363–1371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tan C, Qiao F, Wei P, Chi Y, Wang W, Ni S,
Wang Q, Chen T, Sheng W, Du X and Wang L: DIXDC1 activates the Wnt
signaling pathway and promotes gastric cancer cell invasion and
metastasis. Mol Carcinog. 55:397–408. 2016. View Article : Google Scholar
|
